NCT02284035View on ClinicalTrials.gov

Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 27, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions

AIDS

Interventions

DRUG

Raltegravir/3TC

MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.

DRUG

EFV/TDF/FTC

standard combination therapy

DRUG

ATV/r + TDF/FTC or DRV/r + TDF/FTC

DRUG

DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC

DRUG

EFV plus ABC/3TC or RPV/TDF/FTC

DRUG

ATV/r plus ABC/3TC

DRUG

DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC

DRUG

RAL plus ABC/3TC

DRUG

Other ART regimens

Trial Locations (1)

08036

Hospital Clinic, Barcelona

All Listed Sponsors

lead

Juan A. Arnaiz

OTHER

NCT02284035 - Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine | Biotech Hunter | Biotech Hunter